Cure Parkinson’s has produced a report to determine and highlight the impact of our research funding in the wider Parkinson’s research field since the charity began in 2005. This analysis also gives an opportunity to take stock of our achievements and consider where we need to focus our efforts to further accelerate the search for a cure.
Between 2005-2022, Cure Parkinson’s committed more than £16 million of funding to over 72 different research projects, all with the aim of slowing, stopping or reversing the progression of Parkinson’s.
More than 30 different treatment approaches have been researched through Cure Parkinson’s funding, focused on key areas such as:
- Reducing the accumulation and clumping of proteins in brain cells by improving cell waste disposal
- Reducing inflammation and oxidative stress and damage in the brain cells of people with Parkinson’s
- Improving mitochondrial function in cells (the energy centres) to prevent brain cells dying
- Treatments that might induce the regrowth of brain cells, and dopamine brain cell replacement strategies
Approximately three quarters of the total approaches that have so far been tested remain of interest today as potential Parkinson’s treatments and roughly a quarter have moved into a subsequent stage of research since funding – it is encouraging to have so many of these in development.
Download our Impact Report
Related content
The impact of the International Linked Clinical Trials programme (iLCT)
Since its inception in 2012 the Cure Parkinson’s research team has generated dossiers on 159 potential treatments to be evaluated by the iLCT committee – 32 of these have been tested in 41 different clinical trials, across 17 countries, with more than 4,700 people living with Parkinson’s participating in these trials. Cure Parkinson’s has directed £10.4 million of research funding towards iLCT related projects and the iLCT programme has attracted tenfold this amount in external investment into disease-modifying trials for Parkinson’s. Cure Parkinson’s is collaborating with organisations around the world to get as many clinical trials underway as possible with the ultimate aim of making disease-modifying treatments a reality for people living with Parkinson’s.
